ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 490

Catastrophizing in Rheumatoid Arthritis

Soraya Benamar1, Charlotte Hua2, Jacques Morel3, Françoise Barchechath-Flaisler4, Bernard Combe3, Cédric Lukas3 and Cécile Gaujoux-Viala5, 1Rheumatology, Department of Rheumatology, Nîmes University Hospital and Montpellier University EA 2415, Nîmes, France, 2Department of Rheumatology, Nîmes University Hospital and Montpellier University EA 2415, Montpellier, France, 3University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France, 4Rheumatology, Department of Rheumatology, Nîmes University Hospital and Montpellier University EA 2415, Nîmes, France, 5Department of Rheumatology, Nîmes University Hospital and Montpellier University EA 2415, Nîmes, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Several studies pay a particular attention to catastrophizing. Catastrophizing is a negative cognitive and affective response based on inadequate expression of pain. The objective was to assess catastrophizing level in rheumatoid arthritis (RA) and to determine if there is a link between catastrophizing and physical pain intensity, disease activity, disability, depression and quality of life.

Methods: We performed a systematic review of litterature and search the following databases : PUBMED-MEDLINE, COCHRANE and EMBASE until April 2018. All observationnal, cross-sectionnal and randomized control studies investigating catastrophizing in patients with rheumatoid arthritis were included. Statistical analysis defined pooled mean catastrophizing level, using the Pain Catastrophizing Scale (PCS) and assessed the association with disease activity (DAS28), pain (Numerical Rating Scale NRS) and quality of life (SF36).

Results: On 1494 articles concerning catastrophizing and rheumatic disorders, 22 articles concerned RA patients. Finally, 7 were selected in the meta-analysis including 601 RA patients (mean age 57.4 years old, 67.7% female, mean pooled DAS 28 = 3.4 and mean pooled VAS = 3.8). Mean pooled catastrophizing level at baseline was 14.7 (sd = 11.4) in RA patients. In one study, a RA sample identified 22% of high catastrophizers (defined by PCS > ou = 30). There is a significantly positive correlation between pain catastrophizing and disease activity in 3 studies (r between 0.22 and 0.39, all p<0.01) (Table). Pain is strongly associated with catastrophizing (r=0.71 (p<0.01) for NRS; r = -0.43 (p<0.01) for SF-36 Bodily Pain). Higher PCS scores were significantly associated with higher levels of distress i.e. lower SF-36 Mental Health score (r= -0.52 (p<0.01)). Moreover catastrophizing is significantly associated with reduced physical function (r=-0.35 (p<0.01) for SF36 Physical Function) (Table).

Conclusion: Catastrophizing is rarely measured but it’s a common psychological trait which is clearly associated with disease activity, pain, mental health and physical function. It would be interesting to early detect it in order to adapt pharmacologic and non-pharmacologic treatment.

Table 1 : Correlation coefficient between Pain Catastrophizing Scale(PCS) and variables of interest in RA patients

DAS 28

Pain

Mental Health

Physical Function

PCS

r = 0.33 (p<0.002)

r = 0.39 (p< 0.01)

r = 0.22(p<0.01)

r = 0.71 (p<0.01)*

r = -0.43 (p<0.01)°

r = -0.52 (p<0.01)

r = -0.35 (p < 0.01)

Results are expressed by correlation coefficient (r) and signifiance level (p)
* Numerical Rating Scale
° SF-36 Bodily Pain


Disclosure: S. Benamar, None; C. Hua, Abbvie,BMS, Pfizer, 5; J. Morel, Abbvie, BMS, Celgene, Janssen, Medac, MSD, Novartis, Pfizer, Sanofi, Schering, Roche- Chugai, UCB, 5; F. Barchechath-Flaisler, Roche Pharmaceuticals, 5; B. Combe, Pfizer, UCB, BMS, Janssen, Lilly, MSD, Roche-Chugai, Abbvie, Novartis, 2, 5, 8; C. Lukas, Abbvie, BMS, Celgene, Janssen, MSD, Novartis, Pfizer, Sanofi, Schering, Roche- Chugai, UCB, 5; C. Gaujoux-Viala, Abbvie, BMS, Celgene, Janssen, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi, Roche- Chugai, UCB, 2, 5.

To cite this abstract in AMA style:

Benamar S, Hua C, Morel J, Barchechath-Flaisler F, Combe B, Lukas C, Gaujoux-Viala C. Catastrophizing in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/catastrophizing-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/catastrophizing-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology